PT Indofarma Tbk (ISX:INAF) Total Equity: Rp-706,943 Mil (As of Dec. 2025)


ISX:INAF PT Indofarma Tbk ISX:INAF
8 GF Score
Price Rp126.00
GF Value Rp176.99
! 6 Warning Signs
View Full Analysis

What is PT Indofarma Tbk Total Equity?

PT Indofarma Tbk ISX:INAF 8 Total Equity is Rp-706,943 Mil as of Dec. 2025. GuruFocus rates ISX:INAF with a GF Score™ of 8/100 and a GF Value™ of Rp176.99. The stock has 6 warning signs investors should review.

PT Indofarma Tbk's total equity for the quarter that ended in Dec. 2025 was Rp-706,943 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

PT Indofarma Tbk Total Equity Historical Data

* Premium members only.

The historical data trend for PT Indofarma Tbk's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Indofarma Tbk Total Equity Chart

PT Indofarma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 508,309.91 -6,324.97 -804,152.26 -1,144,041.81 -706,942.61

PT Indofarma Tbk Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,144,041.81 -788,956.02 -807,398.87 -890,937.85 -706,942.61
ISX:INAF
8GF Score
PT Indofarma Tbk ISX:INAF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Indofarma Tbk Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

PT Indofarma Tbk's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=535988.243-1242930.856
=-706,943

PT Indofarma Tbk's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=535988.243-1242930.856
=-706,943

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of Rp-706,943 Mil mean?
PT Indofarma Tbk (ISX:INAF) has a Total Equity of Rp-706,943 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Total Equity too high?
PT Indofarma Tbk's current Total Equity is Rp-706,943 Mil. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Total Equity compare to ZTS and VTRS?
PT Indofarma Tbk's Total Equity of Rp-706,943 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current Total Equity is Rp-706,943 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Total Equity of Rp-706,943 Mil. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Total Equity is Rp-706,943 Mil. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Total Equity is Rp-706,943 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued. The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.

Key valuation signals for ISX:INAF:

  • Total Equity: Rp-706,943 Mil
  • GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
  • GF Score™: 8/100 with 6 warning signs

No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Indofarma Tbk Business Description

Address Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score

Get the complete analysis for ISX:INAF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp126.00
Price
Rp176.99
GF Value